Auxogyn Press Releases

2015

• April 21, 2015

  Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise

  Progyny Raises New Round to Fund Clinical Solutions that Improve Patient Outcomes Progyny, Inc., the new combined entity of Auxogyn, Inc. and Fertility Authority, LLC, announced that it has secured additional capital from investors including Kleiner Perkins Caufield & Byers (KPCB), TPG Biotech, SR One and Merck Serono Ventures. The funding will enable the companyFull story >>... Full Story

• March 26, 2015

  The Eeva™ Test is Now Available to Help IVF Patients in the United States

  First and Only Non-invasive, Predictive Test to Aid in Embryo Selection March 26, 2015, NEW YORK, NY – The Eeva Test is now commercially available in the United States following its recent FDA clearance. This breakthrough technology is designed to help fertility clinics select the best embryos during in vitro fertilization (IVF) to aid in theirFull story >>... Full Story

• March 12, 2015

  Auxogyn and Fertility Authority to Merge

  Auxogyn, Inc. and Fertility Authority, LLC today announced the merger of the two companies. The combined company will be the first to provide fertility patients with easy accessibility to high quality doctors, price transparency and financing, extraordinary clinical expertise, and proprietary clinical solutions under one roof.... Full Story

2014

• October 20, 2014

  Auxogyn Announces Oral Presentations on the Eeva™ Test at the Annual Meeting of the American Society for Reproductive Medicine

  Auxogyn, a company focused on advancing women’s reproductive health by translating scientific discoveries into clinical solutions, today announced oral presentations of the latest data on its Eeva™ Test this week at the 70th Annual Meeting of the American Society For Reproductive Medicine (ASRM) 2014 being held this week in Honolulu, Hawaii.... Full Story

• October 15, 2014

  Auxogyn and RESOLVE: The National Infertility Association Co-Host Panel Discussion on Elective Single Embryo Transfer at the American Society for Reproductive Medicine Annual Meeting

  Distinguished Panel Discussion entitled “Understanding Patients’ Perspectives on Elective Single Embryo Transfer” Shares Results of Nationwide IVF Patient Survey with Physicians to Help Improve Patient Education   Menlo Park, CA and McLean, VA October 15, 2014 – Auxogyn, a leader in women’s reproductive health, and RESOLVE: The National Infertility Association today announced their joint sponsorshipFull story >>... Full Story

• October 13, 2014

  Auxogyn Announces Pilot Study to Evaluate Use of the Eeva™ Test for Patients Who Elect to Undergo Elective Single Embryo Transfer

  Randomized Controlled Pilot Trial Initiated at one of the Top IVF Research Clinics in the United States MENLO PARK, Calif. – October 13, 2014 – Auxogyn, Inc. a company focused on advancing women’s reproductive health by translating scientific discoveries into clinical solutions, today announced that Brigham and Women’s Center for Infertility and Reproductive Surgery (CIRS)Full story >>... Full Story

• August 4, 2014

  Social Media Fundraising Campaign Raises £2000 for Charity Supporting Infertility

  Auxogyn, a leader in women’s reproductive health and the developer of the Eeva Test, a test clinically proven to assess embryos with the highest development potential for transfer, presented a cheque for £2000 to Infertility Network UK (I N UK), a patient charity solely devoted to help people who are struggling to conceive, following its successful social media fundraising campaign ... Full Story

• July 1, 2014

  Auxogyn Announces Presentations on the Eeva Test at the Annual Meeting of the European Society of Human Reproduction and Embryology

  Auxogyn, a leader in women’s reproductive health, today announced the presentations of the latest data on its Eeva™ Test at the 30th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) 2014. The meeting will be held June 29^th through July 2^nd in Munich, Germany.... Full Story

• June 10, 2014

  Auxogyn Receives FDA Clearance for Its Eeva™ System

  Auxogyn, Inc. a leader in women’s reproductive health, today announced that its first product, the Eeva System, received clearance from the U.S. Food and Drug Administration through its de novo classification process, a regulatory pathway for select novel, low- to moderate-risk medical devices that are first-of-a-kind. ... Full Story

• May 6, 2014

  First-Of-Its-Kind “Be Social” Fundraising Campaign Kicks-Off to Benefit Infertility Network UK

  The Eeva™ Test is launching its Be Social (#BSOCIAL4INUK) campaign to raise money for Infertility Network UK (I N UK), a patient charity solely devoted to help, support and provide information to people who are struggling to conceive... Full Story

• April 3, 2014

  Auxogyn Announces Exclusive License Agreement for Eeva Test

  Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, will receive commercialization rights from Auxogyn for the Eeva Test, which is designed to provide objective embryo viability data to IVF clinicians... Full Story

• January 29, 2014

  Vancouver’s Genesis Fertility Clinic is first in Canada to offer groundbreaking Early Embryo Viability Assessment (EEVA™) test

  Genesis Fertility Centre, an in vitro fertilization (IVF) clinic in Vancouver, today announces it is the first clinic in Canada, and the first commercial clinic in North America, to offer patients the Early Embryo Viability Assessment (Eeva) Test... Full Story

• January 6, 2014

  New Clinical Data on Day 3 Embryo Transfers Using Eeva™ Technology Presented at the Association of Clinical Embryologists 2014 Conference

  Results of a clinical study utilizing the Eeva™ Technology by Auxogyn, that showed similar pregnancy rates among patients when embryos were transferred on Day 3 utilizing Eeva information versus Day 5 blastocyst transfers relying on morphology alone, were presented today... Full Story

2013

• November 1, 2013

  New ground-breaking IVF Technology now available in two Spanish clinics

  With an increasing number of UK couples travelling abroad for fertility treatment and Spain being amongst the most popular of the preferred destinations, both FIV Marbella and IVF Spain are proud to be the first infertility clinics to make a ground-breaking new approach to IVF commercially available in Spain... Full Story

• October 31, 2013

  Renowned UK IVF clinic reflects on success with Eeva™: Enhanced patient experience a key benefit of new IVF technology

  Following the birth of the first Eeva baby conceived at the Glasgow Centre for Reproductive Medicine (GCRM), one of the UK’s most innovative IVF clinics and supporter of National Infertility Awareness Week, the clinic identifies the benefits of using the ‘Early Embryo Viablity Assessment’ (Eeva) test, a ground-breaking new approach to IVF that improves embryo selection... Full Story

• July 25, 2013

  Auxogyn Announces Strategic Partnership with Valencia Infertility Institute

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, today announced it has entered into a strategic partnership with the Valencia Infertility Institute (IVI), a global leader in reproductive medicine with 23 clinics throughout the world... Full Story

• July 9, 2013

  Auxogyn Wins Prestigious Grant for Fertility Innovation

  Auxogyn, Inc., a privately held company that is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into effective clinical tools, has been selected as the recipient of the prestigious Merck Serono Grant for Fertility Innovation (GFI) award... Full Story

• July 2, 2013

  Auxogyn to Present New Data at the ESHRE 2013 Annual Meeting in London

  Auxogyn Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, today announced the presentation of the latest data on its Eeva™ Test at the 29th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) 2013... Full Story

• June 14, 2013

  Baby Eva named after pioneering IVF test - First baby born in Scotland using new ground-breaking IVF technology

  Auxogyn announces the birth of the first baby in Scotland to be born using a ground-breaking new approach to IVF, the 'Early Embryo Viability Assessment' (Eeva™) test, that improves embryo selection... Full Story

• June 5, 2013

  First baby born in the UK using Early Embryo Viability Assessment (Eeva) test

  Auxogyn, Inc. announced today the birth of one of the first babies to be born after embryologists used the Early Embryo Viability Assessment (Eeva™) Test to select and identify the most viable embryo for implantation into the mother’s womb... Full Story

• May 22, 2013

  Auxogyn Selected to Present at European BioEquity Conference in Stockholm

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, announced that Lissa Goldenstein, CEO and President of Auxogyn will be a featured speaker at the 14th European BioEquity Conference being held today in Stockholm, Sweden... Full Story

• May 15, 2013

  Auxogyn Honored as a Finalist in the Red Herring 2013 Top 100 North America Award

  Auxogyn, Inc. announced today that it has been selected as a finalist for Red Herring's Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region... Full Story

• May 7, 2013

  Auxogyn Announces Availability of Groundbreaking IVF Test, Eeva™, at Bourn Hall Clinic; Designed to Improve Outcomes

  The cutting-edge, new Early Embryo Viability Assessment™ (Eeva) Test designed to improve in vitro fertilization (IVF) outcomes is now available to couples seeking IVF treatment in East England. Using intelligent computer vision software to analyze key scientifically and clinically validated cell-division parameters, the Eeva Test is the first and only non-invasive IVF test... Full Story

• February 28, 2013

  Auxogyn Appoints Women’s Health Leader, Kathryn A. Tunstall, To Board of Directors

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced the appointment of Kathryn A. Tunstall to the company's Board of Directors... Full Story

• January 24, 2013

  Auxogyn Announces European Expansion of New Non-Invasive Early Embryo Viability Assessment (EEVA™) Test With Availability at First Clinic in Ireland

  Auxogyn Inc. today announced that Sims IVF is the first fertility clinic in Ireland to offer patients the Early Embryo Viability Assessment (Eeva) Test... Full Story

• January 3, 2013

  Auxogyn Announces First European Patent for EEVA™ Test

  We are thrilled with the European Patent Office’s decision to issue this patent,” said Lissa Goldenstein, president and chief executive officer of Auxogyn. “This European patent provides further validation that bodies governing intellectual property worldwide recognize the inventive work done at Stanford University in the field of human embryology... Full Story

2012

• December 27, 2012

  Fertility Road: Embryo Monitoring Designed to Improve IVF Outcomes

  Revolutionary new non-invasive test that uses intelligent imaging software to measure and predict with more accuracy which embryos will likely grow to the blastocyst stage... Full Story

• December 4, 2012

  Auxogyn Announces Publication of New Data Key to Identifying Which Developing Human Embryos are Most Likely to Result in Successful IVF Pregnancy

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced new data key to identifying which developing human embryos are the most likely to result in successful pregnancies during in vitro fertilization (IVF) procedures... Full Story

• Auxogyn Announces IVF Research Using its EEVA Test Awarded Top Honor at Fertility Society of Australia Scientific Meeting

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that research involving the use of the company’s flagship product, the Early Embryo Viability Assessment (Eeva) Test, was recognized by the Fertility Society of Australia at its 2012 Scientific Meeting with the Ferring “Best Scientific Paper Award... Full Story

• October 22, 2012

  Auxogyn Presents New Data Validating Eeva’s Ability to Predict Blastocyst Development in IVF By Day 3 With High Specificity and Consistency

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced two presentations describing new data from a prospective, cohort study conducted at multiple independent centers... Full Story

• October 18, 2012

  Merck Serono and Auxogyn Announce Collaboration on EEVA™ Test

  Merck Serono, a division of Merck, Darmstadt, Germany, and Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that they have entered into a strategic agreement focused on Auxogyn’s proprietary Early Embryo Viability Assessment (Eeva) Test... Full Story

• October 11, 2012

  Auxogyn Strengthens Intellectual Property Rights for EEVA™ Test

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that the U.S. District Court for the Northern District of California has ruled in favor of Auxogyn and Stanford University and dismissed a patent lawsuit initiated by Unisense Fertilitech... Full Story

• September 17, 2012

  Auxogyn and Hewitt Fertility Center Announce First Availability of New Non-Invasive Early Embryo Viability Assessment (EEVA) Test in the European Union

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced the launch of its Early Embryo Viability Assessment (Eeva) Test in the European Union (EU), with the first installation at the Hewitt Fertility Centre in Liverpool... Full Story

• July 23, 2012

  Auxogyn Receives CE Mark for Non-Invasive Early Embryo Viability Assessment (EEVA) Test

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that it has received CE mark approval to market its flagship product, the Early Embryo Viability Assessment (Eeva) Test, which is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy... Full Story

• July 2, 2012

  Auxogyn Presents New Data Showing the Ability of EEVA™ to Non-Invasively Predict Embryo Advancement With Increased Accuracy

  Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today presented data showing the ability of its flagship product, the Early Embryo Viability Assessment (Eeva) Test, to predict embryo advancement with a new level of accuracy. The Eeva™ Test uses intelligent computer vision software to measure key parameters from video images and predicts with high accuracy at the cleavage stage which embryos will likely grow to the blastocyst stage... Full Story

• June 19, 2012

  Auxogyn and Reproductive Medicine Associates of New Jersey Partner to Advance In Vitro Fertilization Research

  Auxogyn, Inc., a company at the forefront of reproductive health innovation, today announced the commencement of a groundbreaking research study with Reproductive Medicine Associates of New Jersey (RMANJ), an internationally-renowned fertility clinic that has pioneered and successfully implemented cutting-edge clinical advancements to more accurately detect healthy embryos for patients undergoing in vitro fertilization (IVF)... Full Story

• June 5, 2012

  Auxogyn Raises $18 Million in Series B Funding

  Auxogyn, Inc., a privately-held company advancing women’s reproductive health, today announced it raised $18 million through a Series B financing. The proceeds will be used to support regulatory clearance and commercial launch of Auxogyn's Early Embryo Viability Assessment, Eeva, a non-invasive test designed to provide objective information regarding the viability of embryos during in vitro fertilization (IVF) procedures... Full Story

• February 9, 2012

  Auxogyn Takes Top Honor As “Most Promising Company” at Personalized Medicine World Conference 2012

  Auxogyn, Inc., a privately-held company advancing women’s reproductive health, announced today that the Personalized Medicine World Conference (PMWC) and Prescience International selected the Auxogyn as the ‘Most Promising Company’ at PMWC2012 annual conference, held January 23-24, 2012... Full Story

• February 2, 2012

  Auxogyn Announces the Close of the Final Tranche of its Series A Financing, Bringing the Total Funding to $20 Million

  Auxogyn, Inc., a privately-held company focused on advancing women’s reproductive health, today announced the close of the final tranche of its Series A financing, bringing the total funding to $20 million. The initial tranche was placed in May 2010, and investors in the round include Kleiner Perkins Caufield and Byers, TPG Biotech and Merck Serono Ventures... Full Story

2011

• July 4, 2011

  Auxogyn Announces Initiation of Clinical Study for Non-Invasive Embryo Assessment Technology Used During In Vitro Fertilization

  Auxogyn, Inc., a privately held medical technology company focused on women’s reproductive health, today announced that it initiated a multi-center clinical study to validate its early embryo viability assessment (Eeva™) System for use in in vitro fertilization (IVF)... Full Story

• June 27, 2011

  Auxogyn Announces Issuance of Key Patent Covering Predictive Embryo Assessment Parameters for In Vitro Fertilization

  Auxogyn, Inc., a privately held medical technology company focused on women’s reproductive health, today announced that the U.S. Patent and Trademark Office (USPTO) issued patent number 7,963,906 covering three predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn’s early embryo viability assessment (Eeva™) System... Full Story

2010

• October 4, 2010

  Auxogyn Licenses Non-Invasive Embryo Assessment Technology from Stanford University

  Auxogyn, Inc., a privately held medical technology company focused on women’s reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures... Full Story